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Abstract
Summary Osteoporosis has become a major health concern,
carrying a substantial burden in terms of health outcomes
and costs. We constructed a model to quantify the potential
effect of an additional intake of calcium from dairy foods on
the risk of osteoporotic fracture, taking a health economics
perspective.
Introduction This study seeks, first, to estimate the impact
of an increased dairy consumption on reducing the burden
of osteoporosis in terms of health outcomes and costs, and,
second, to contribute to a generic methodology for assessing
the health-economic outcomes of food products.
Methods We constructed a model that generated the num-
ber of hip fractures that potentially can be prevented with
dairy foods intakes, and then calculated costs avoided,
considering the healthcare costs of hip fractures and the
costs of additional dairy foods, as well as the number of
disability-adjusted life years (DALYs) lost due to hip
fractures associated with low nutritional calcium intake.
Separate analyses were done for The Netherlands, France,
and Sweden, three countries with different levels of dairy
products consumption.
Results The number of hip fractures that may potentially
be prevented each year with additional dairy products
was highest in France (2,023), followed by Sweden
(455) and The Netherlands (132). The yearly number
of DALYs lost was 6,263 for France, 1,246 for Sweden,
and 374 for The Netherlands. The corresponding total
costs that might potentially be avoided are about 129 mil-
lion, 34 million, and 6 million Euros, in these countries,
respectively.
Conclusions This study quantified the potential nutrition
economic impact of increased dairy consumption on oste-
oporotic fractures, building connections between the fields
of nutrition and health economics. Future research should
further collect longitudinal population data for document-
ing the net benefits of increasing dairy consumption on
bone health and on the related utilization of healthcare
resources.
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Introduction
Health benefits of dairy foods, which provide a large variety
of essential nutrients such as minerals, vitamins, and pro-
teins, are widely recognized [1]. Dairy foods, consumed by
many people throughout the Western world as part of the
daily diet [2, 3], are a determinant of human health and well-
being. Although the extent of those effects has not been
completely unfold, some of the reported benefits concern
the area of cardiovascular diseases, colorectal cancer, obe-
sity and type 2 diabetes [4–6]. Several studies have docu-
mented the link between the intake of dairy foods and
osteoporosis, associating low dietary calcium intake with
decreased bone density and osteoporotic fractures, as dairy
products consistently provide 60 % to 70 % of daily calcium
intakes [7–12]. In a review by McCarron and Heaney on the
effects of dairy products in several medical conditions, they
concluded that in the USA intake of the recommended
quantities of dairy products would yield 5-year savings
(limited to healthcare costs) of $209 billion. Of this,
$14 billion relate to savings on the healthcare costs for
osteoporosis (limited to treating fractures) [13]. Over the
past decades, osteoporosis has become a major health con-
cern, estimated to affect over 200 million people worldwide
[14, 15]. The disease carries a substantial burden. First,
osteoporosis increases the risk of fractures, associated with
increased mortality, increased morbidity, limitations in
physical function, pain, and losses in health-related quality
of life [16, 17]. Second, osteoporotic fractures considerably
increase healthcare costs, in both inpatient and outpatient
settings, as has been confirmed by several studies [18–20]
Calcium and vitamin D supplementation, anti-osteoporotic
drugs, and exercise programs have been shown to be effective
in reducing the risk of fractures [21, 22]. However, in daily
practice non-compliance appears to be a significant problem
with specific anti-osteoporotic therapy and with calcium and
vitamin D supplementation as well [23, 24]. This pro-
vides a rationale for supporting a more food-oriented preven-
tive approach of osteoporosis.
The purpose of this study was to explore the relationship
between a food-related health condition and its potential
impact on health care expenditures. Currently, the literature
contains hardly any relevant studies on the impact of dairy
foods on healthcare costs or cost-effectiveness [25, 26].
Despite the fact that the effects of foods on health are
increasingly recognized, there is no accepted, proven meth-
odology to assess the health-economic impact of foods in
the general population. The scarcity of estimations on the
health-economic impact of foods stands in sharp contrast
with the ever-growing evidence on the cost-effectiveness of
(public) health technologies [27, 28]. Obviously, the evi-
dence most adapted to a general population setting as well to
the long latency periods for nutrition-related diseases mainly
has to come from prospective cohort studies with disease
events and death as outcome.
In this paper, we propose an approach for estimating the
potential nutrition economic impact of dairy products on the
burden of osteoporosis in the general population over
50 years of age. The aims are first, to quantify the burden
of osteoporosis (in terms of costs and health outcomes) and
to estimate the potential impact of increasing dairy foods
consumption on reducing this burden. These calculations
were performed for France, The Netherlands, and Sweden.
Secondly, this study aims to contribute to the development
of a generic methodology for assessing the health-economic
outcomes of food products.
Materials and methods
Data sources
Systematic literature reviews were performed using the fol-
lowing sources: PubMed library, Cochrane library, Embase,
and Scopus; Health-economic databases, such as EURO-
NHEED, the NHS Economic Evaluation Database (NHS
EED), and the CEA Registry maintained by the Center for
the Evaluation of Value and Risk in Health.
We used the following search criteria: major search terms
were osteoporosis, fracture, bone, dairy, milk, calcium, vita-
min D, intervention, supplementation, mortality, quality of
life, QALY, medical consumption, costs, cost-effective, cost-
benefit, and economic evaluation; peer-reviewed articles were
included; only articles in English or Dutch were taken into
account; the site of the fracture (at least studies had to distin-
guish hip fractures from other fractures like spine and wrist);
review studies that did not include new data were excluded;
studies published in 1995 and onwards were included; due to
insufficient data available in the literature on all age groups,
the search was restricted to age 50 years and older.
The studies retrieved by the literature search were used to
arrive at valid estimations of the following parameters,
which were needed as an input to the model:
– Relationship between calcium intake by dairy foods and
osteoporotic fractures indicated by relative risk estimates
or odds ratios.
– Costs of treating fractures in the first year and in sub-
sequent years.
– Mortality risk associated with osteoporotic fractures.
– Health-related quality of life (‘utilities’) of healthy people
and of people who are experiencing an osteoporotic frac-
ture; studies had to use generic (not disease specific),
preference based instrument to come to a utility.
The way how the above mentioned parameters were
retrieved or calculated in each study was critically judged.
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Studies that divided their results in age classes were pre-
ferred. Studies that evaluated the effects of a specific treat-
ment modality (in a subgroup of patients), rather than
including a ‘broad’ population sample of patients with frac-
tures, were excluded.
We derived data from national databases for each coun-
try, i.e. Statistics Netherlands (CBS; www.cbs.nl), National
Institute of Statistics and Economic Studies (INSEE;
www.insee.fr), and Statistics Sweden (SCB; www.scb.se).
For The Netherlands, we also used results of the Dutch
National Food Consumption Survey [29].
The data needed to build our nutrition economic model
can be found in the flow diagram presented in Fig. 1.
Study population and countries
The populations of interest were men and women (of any
ethnicity) from the general population of Western Europe
aged 50 years and over. This includes individuals treated
and not treated for osteoporosis. We specifically looked for
data that divided the (general) population by sex and 5-year
age classes.
Health-economic studies should take into account differ-
ences between countries. In this case, it can be expected that
dairy intakes may differ considerably between different
regions in Europe [3]. Moreover, other differences be-
tween the populations of several countries may affect the
occurrence of osteoporosis, such as lifestyle, the availabil-
ity and quality of healthcare, climate, genetic predisposi-
tion, etc. Furthermore, treatment pathways, costs of
healthcare, and cost prices of dairy food products will
differ. To get insight in country differences we will pres-
ent the model outcomes for The Netherlands, Sweden, and
France, a choice based on different dairy intakes and on
the availability of country specific public health data and
nutritional surveys.
DALY’s 
Survivalrate 
Costs hip fracture first 
year
Costs avoided 
Years of life lost Loss QoL  
Incidence hip # 
Total population 
Proportion Insufficient Ca-intake (ICI) 
Relative Risk hip fracture due to ICI 
Mortality (after hip fracture) 
Mortality chance (general) 
Prevented mortality 
Life expectancy 
Utility hip# 
Costs hip fracture first year 
Costs hip fracture subsequent years 
Costs dairy food 
Costs hip fracture 
subsequent years (lifetime 
after 50) 
Costs dairy foods 
(lifetime after 50) 
Population Attributive Risk 
Hip fractures avoided 
Fig. 1 Flow diagram of the
nutrition-economic model for
hip fracture as outcome of
osteoporosis
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Study focus and perspective
Because dairy food products are the major source of
calcium in the Western European diet, this study aimed
at quantifying the potential impact of increasing dairy
foods consumption on the occurrence of osteoporotic hip
fractures in people with an inadequate calcium intake.
We defined low calcium intake as a daily intake equal to
or less than 600 mg, which is approximately half of the
daily intake (DRI) recommended by the International
Osteoporosis Foundation [30, 31]. We used the calcium
content of dairy foods as a marker to model the effect on
osteoporotic hip fractures.
The study primarily analysed the costs and health
impact from a healthcare perspective. In addition to this,
we broadened the perspective to a more societal approach
by including the costs of dairy foods made by those
persons who could be prevented from having a hip
fracture associated with low calcium intake. The study
took a life-long time horizon, which implies that both
costs and effects were taken into account from the oc-
currence of hip fracture till death. We used the discount
rates recommended in the Dutch guidelines for pharmaco-
economic research (that is, 4 % for costs and 1.5 % for
effects) [32].
Analytical techniques and main outcome measures
Using the risk estimate found in the literature, we calculated
the Population Attributive Fraction (PAF). This represents
the percentage of all hip fractures (among exposed and
unexposed) that can be attributed to low calcium intake, as
expressed in the formula:
PAF ¼ Pe RR 1ð Þ½ = Pe RR 1ð Þ þ 1½ 
where: Pe 0 prevalence of risk factor in the population; RR 0
relative risk for hip fracture due to low calcium intake [33].
Next, we calculated the absolute amount of hip fractures
that potentially can be prevented with additional calcium
intake. In epidemiology, this number is known as the ‘po-
tential impact fraction’ (PIF), i.e. the potential reduction in
disease prevalence resulting from a risk factor intervention
program. It is calculated by multiplying (per age class) the
incidence of hip fractures with the corresponding PAF for
that age class [33]. In a formula:
PIF ¼ I  N=1; 000  PAF
where: I 0 incidence of hip fractures (per 1,000); N 0 total
population per age class; PAF 0 population attributive frac-
tion. This measure will be used in the further calculations in
the model, i.e. the outcomes disability-adjusted life years
(DALYs) and costs avoided will be referring to the total
population per age class.
In order to assess the potential impact of increased dairy
consumption on the prevention of osteoporotic hip fractures,
our model includes two main outcome measures. The first is
costs avoided. These are calculated by determining the costs
of treating hip fractures (i.e. healthcare costs made in the
first year after a fracture, as well as those made in subse-
quent years) and subsequently subtracting the costs made
for extra dairy food consumption. In the primary analyses,
only the costs of dairy food products made by those people
in whom a hip fracture actually could be avoided by extra
dairy food consumption are taken into account: we calculat-
ed how many dairy products people with a low calcium
intake would have to consume to reach the DRI. The data
on the calcium content of dairy products were taken from
the Dutch Food Composition Database (NEVO) [34]. We
took an average of different types of dairy products—in-
cluding milk, yogurt, fresh cheese, and cheese—represent-
ing the common consumption pattern in the population for
each of the three countries. For example in The Netherlands,
extra 650 mg calcium per day equaled: 200 milliliter low-fat
milk (0242 mg calcium) + 125 milliliter low-fat yogurt
(0166 mg calcium) + 30 gram young cheese (0237 mg
calcium). These data were combined with country-specific
unit cost prices of dairy products, derived from general
market prices (September 2010 prices). To facilitate com-
parisons, we used the prices of national supermarkets (pref-
erably the market leaders) rather than those of traditional
shops. Finally, we arrived at total costs per day/year, repre-
senting the total additional costs if people with a low calci-
um intake raise their intake up to the recommended level by
increasing their dairy foods consumption.
The second main outcome of our model is the number of
lost DALYs, which represent a widely-used summary indi-
cator of public health [35]. DALYs are the sum of life years
lost due to premature mortality and years lived with disabil-
ity adjusted for severity. In other words, the basic formula
for DALYs is:
DALY ¼ YLLþ YLD
where: YLL 0 years of life lost due to premature mortality;
YLD 0 years of healthy life lost as a result of disability.
The DALY measure was used to calculate the life years
lost and the loss in quality of life due to hip fracture
caused by low calcium intake (see Fig. 1). We used
country- and age-specific mortality rates due to hip frac-
ture. In this respect, it is important to distinguish between
excess mortality rates, i.e. the proportion of the population
suffering from a hip fracture that dies, and general popu-
lation mortality, i.e. the proportion of the general popula-
tion that dies due to hip fracture [36]. Considering the
data available, and for reasons of comparability between
countries, we used the mortality rates after hip fracture in
the general population.
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Sensitivity analyses
We conducted sensitivity analyses to verify to what extent
certain assumptions might have influenced the results. Plau-
sible ranges of uncertain parameters were obtained from the
published literature or by varying the estimates by a certain
percentage in each direction. The following parameters were
varied:
(1) The relative risk expressing the relationship between a
low calcium intake and the occurrence of hip fractures,
and the proportion of the general population with a low
calcium intake.
(2) Long-term quality of life impact of hip fractures.
(3) Discount rates.
(4) Dairy food costs.
The results of the sensitivity analyses are expressed in the
outcome measures of DALYs lost and total costs avoided.
Results
Table 1 shows the data used as input in the model. For the sake
of clarity, the table pools the data from both sexes and all age
categories. In the model itself, all input variables were divided
into sex and age categories (i.e. 50–54, 55–59, 60–64, 65–69,
70–74, 75–79, 80–84, ≥85 years). The risk factor for a hip
fracture due to low calcium intake was based on a study by
Cumming et al., and amounted to 1.08 [37]. The incidence of
hip fractures in both men and women in Sweden appeared to
exceed that of The Netherlands and France. Moreover, in all
countries, it shows that the incidence of hip fractures in wom-
en is higher compared with men. Furthermore, the incidence
of hip fractures and mortality rates after hip fracture increase
substantially with age especially in the age categories of 70
and above. As explained above, themortality figures in Table 1
refer to the mortality after hip fracture in the general popula-
tion. It appeared that, up to the age of 80 years, the mortality
data for Sweden exceed those for The Netherlands and France,
probably because of the high incidence rates of hip fracture in
Sweden compared to the other countries. In the first year after
hip fracture, the average loss of quality of life (‘utility’) was
calculated at 0.22; while in the following years, the average
loss of quality of life was 0.08. Daily costs of additional dairy
products were calculated at € 0.44, € 0.64, and € 0.68, for The
Netherlands, France, and Sweden, respectively.
Main outcomes
With a distinction according to age class, Fig. 2 shows the PIF,
indicating the number of hip fractures that could potentially be
prevented each year with additional calcium intake. All age
classes taken together, the PIF is highest in French women
(1,565), followed by Swedish women (307). Across all age
classes, the PIF number was relatively low in The Netherlands
(103), compared with France and Sweden.
The prevented mortality is relatively low for all three
countries: all age classes and both sexes taken together, the
number of deaths prevented per 10,000 persons experienc-
ing a hip fracture is 5.1 (Sweden), 2.4 (France), and 0.4 (The
Netherlands), respectively. This can be explained by the fact
that the PAF (i.e. the percentage of hip fractures attributed to
low calcium intake) is rather low (The Netherlands, 0.8 %;
France, 3.1 %; and Sweden, 2.2 %).
Figure 3 shows the yearly number of DALYs lost, repre-
senting the burden of hip fractures due to low calcium
intake. In all countries, the number of DALYs lost appears
to increase with age. In total, the yearly societal burden of
hip fractures due to low calcium intake appeared to be 6,263
DALYs for France, 1,246 DALYs for Sweden, and 374
DALYs for The Netherlands.
Figure 4 shows the total costs that can potentially be
avoided when the risk of hip fractures is decreased by the
additional consumption of dairy foods. These discounted costs
(which are actually savings) represent the difference between
the costs of treating hip fractures and the costs of extra dairy
foods. The potential savings on the costs of treating hip frac-
tures exceeded the costs of extra dairy foods in all age classes
in all three countries. The total costs potentially avoided were
largest in women in France (€ 100,311,274) followed by
women in Sweden (€ 23,912,460) and The Netherlands
(€ 5,121,041). Themain part of these costs can be prevented in
the older age categories, i.e. from 70 years onwards.
Sensitivity analyses
We varied the PAF by changing the risk factor for a hip
fracture associated with low calcium intake (using the 95 %
confidence interval of 1.02 to 1.16) [37], as well as by
changing the proportion of people with a low calcium in-
take. Both outcomes of the model (i.e. number of DALYs
lost and costs avoided) are sensitive for the relative risk of a
hip fracture, from age category 70–74 onwards. For exam-
ple, in the case of The Netherlands, the number of DALYs
lost in women aged 85 years and above (in the primary
analysis calculated at 185) ranged from 46 to 367. In this
subgroup, varying the relative risk made the costs avoided
fluctuate between € 0.6 million and € 5.1 million (in the
primary analysis calculated at € 2.6 million). When chang-
ing the proportion of people with a low calcium intake with
10 %, the number of DALYs and the costs avoided will
concomitantly change with approximately 10 %.
The quality of life after hip fracture during subsequent years
was changed using a range of 0.05 and 0.12, where 0.08 was
used in the primary analyses [38]. This did not substantially
change the outcomes for the three countries under study.
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Table 1 Summary of data used and its sources (all age categories pooled)
Parameter Data (mean over both sexes) (>50 years) Data sources
NL FR SE NL/FR/SE
Percentage of low calcium intake (i.e., <600 mg/day)
in the general population
8 % 40 % 31 % [11, 43, 69]
Recommended intake of calcium in the elderly (mg/day) 1,300 1,300 1,300 [30]
Incidence of hip fractures (per 1,000)f 53.9 35.2 64.7 RIVMa [36, 70]
Size of the general population (absolute numbers)f 5,603,463 21,689,920 3,378,795 CBSb/INSEEc/SCBd
Relationship between a low calcium intake and hip
fractures: RR (95 % CI)
1.08 (1.02-1.16) 1.08 (1.02-1.16) 1.08 (1.02-1.16) [37]
Costs of hip fractures (in Euro)f [59, 71, 72]
-First year after the fracture € 129,210 € 114,602 € 114,025
-Subsequent years € 22,815 € 50,488 € 50,700
General mortality following hip fractures (per 10,000) 28.7 35.9 99.5 CBS [36, 73]
Life-expectancy (years) and mortality (chance) in the
general population (at 50 years)
28.9 30.5 30.6 CBS/INSEE/SCB
0.038 0.033 0.033
Health-related quality of life following hip fractures
(i.e., the reduction in quality of life measured
on a scale from 0 to 1)
[38]
-First year after the fracture 0.22 0.22 0.22
-Subsequent years 0.08 0.08 0.08
Unit cost prices of dairy foods; ‘intervention
costs/ day’ (in Euro)e
€ 0.44 € 0.64 € 0.68 Albert Heijn (www.albert.nl)
Carrefour (www.carrefour.fr)
ICA (www.ica.se)
CBS Statistics Netherlands, INSEE Statistics France, IOF International Osteoporosis Foundation, SCB Statistics Sweden
a http://www.nationaalkompas.nl
b http://www.cbs.nl
c http://www.inseee.fr
d http://www.scb.se
e Corresponding to an extra 650 mg calcium per day; September 2010 prices
f Summed over the eight distinguished age categories
Fig. 2 Potential impact fraction
(absolute numbers)
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In the primary analyses, a discount rate of 4 % for costs
and 1.5 % for health effects was used. We compared this to
the results without discounting. The analysis showed that
both outcomes (DALYs and costs avoided) were, as expected,
slightly lower than when discounting is applied.
Finally, a calculation of costs avoided was made in case
dairy food costs were omitted from the model. The reason to
do so is that the extra dairy food consumption will most
likely be a substitute for other food products. This analysis
revealed slightly higher costs savings (3 %).
Discussion
In this study, we quantified the potential nutrition economic
impact of increasing dairy consumption by people with low
calcium intake on the occurrence of osteoporotic hip frac-
tures. The core of the model was the absolute amount of hip
fractures that potentially can be prevented. We particularly
paid attention to the potential preventive effect of increasing
calcium intake on the occurrence of hip fractures, DALYs,
and costs in the population at risk. By including several,
geographically distinct European countries with different
food patterns, it was shown how the nutrition economic
impact of dairy foods on hip fractures varies between
countries with different incidence rates of hip fractures,
different numbers of people with low calcium intake, and
different costs of healthcare and costs of dairy foods. Our
study concentrated on middle-aged and older groups, aged
50 years and over.
One may question to which extent the principles of health
economics apply to food products and dietary habits. Will it
Fig. 3 DALYs lost, representing
the burden of hip fractures in
relation to low calcium intake
Fig. 4 Costs avoided
(first and subsequent years
after hip fracture) through im-
proved dairy foods consumption
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simply come down to applying the principles and methods
of health economics, or would it be required to develop
‘nutrition economics’, as a novel subarea of health econom-
ics [25]? Next to similarities between health economics in
general and ‘nutrition economics’ in particular, there also
will be differences, for example relating to differences in
study populations and relating to the fact that food-related
changes are often relatively small and only observable over
a long time window [39, 40].
There is a need to work towards a generic methodology
to assess the impact of foods on health, well-being, and
costs. In making this effort, osteoporosis offers an excellent
case study: it represents a heavy burden and has a high
prevalence, the disease is progressing slowly and has an
early onset (several decades before it actually manifests
itself), and is associated with food consumption [9].
In accordance with earlier studies [41], the incidence of
hip fractures was highest for Sweden, compared to The
Netherlands and France. One explanation for these inter-
country differences may be related to different levels of
calcium intake between countries’ populations. However,
there will be other explanations as well, which is why there
is no one-to-one relationship between calcium intake and
rates of hip fractures (as the numbers for the countries
included in this study demonstrate). Plausible other hypoth-
eses for these inter-country differences include genetic pre-
disposition and lifestyle factors (nutritional patterns in
general, physical activity, etcetera) [42]. The highest PIF
was found in French women, which can be explained by
the relatively large proportion of the French female popula-
tion with a low calcium intake. In The Netherlands, this PIF
number was much lower, relating to the fact that the Dutch
consume large amounts of dairy foods [43, 44]. It should be
noted that the food consumption studies used measured
calcium intake from all food products, not solely dairy
foods. However, dairy foods contributed by far the most to
calcium intake [11, 43].
The yearly societal burden of hip fractures associated with
low calcium intake appeared to be 374 DALYs for The
Netherlands, 6,263 DALYs for France, and 1,246 DALYs
for Sweden. The potential savings on the costs of treating hip
fractures exceeded the costs of extra dairy foods in all three
countries. Total costs avoided were largest in France, mainly
due to the relatively high PIF found in France. As mentioned
before, the main calculations rested on the assumptions that
all these hip fractures are indeed prevented. This might raise
questions about compliance. It is known that compliance
with current anti-osteoporotic drugs is rather low, and opti-
mal anti-fracture efficacy is not always achieved in clinical
practice [23, 45, 46]. In a recent study [47], dairy food has
been shown to be an appropriate vehicle to supplement extra
calcium and other minerals, with good compliance compared
to that reported for supplements [48].
The daily costs of additional dairy were lowest in The
Netherlands, compared to France and Sweden. This corre-
sponds with the findings of a European Commission report,
which analysed price differences of supermarket goods
across Europe [49]. In the primary analysis, costs of addi-
tional dairy foods were applied only to those persons who
actually could be prevented from having a hip fracture due
to low calcium intake. This might overestimate the outcome
of the model, as, from a primary prevention point of view,
one needs to expose the whole population at risk to extra
calcium intake by means of extra dairy consumption. It
might be assumed though that when the people at risk
start taking extra dairy, this will be a substitution—either
full or partly—for other food products. Hence, in this
situation, the total cost of dairy foods might only be
slightly higher. If a strict health care perspective is adop-
ted, the costs of purchasing dairy foods as part of a
normal diet do not need to be taken into account. The scope
of the analysis can be limited to the health care costs made for
hip fractures.
Some remarks should be made on the data used as input
in the calculations, especially regarding the relative risk for
hip fracture associated with low calcium intake. First,
reviews with pooled study results do not take into account
different starting levels of calcium intake. This might ham-
per the interpretation of the effect size of low calcium intake
on the occurrence of hip fractures. The data existing in the
literature did not allow us to correct for a different start point
in calcium intake of these elderly in our model. This prob-
ably resulted in an underestimation of the effect size of the
main outcomes in this study. Second, the relative risk for hip
fracture was derived from the meta-analysis of Cumming et
al. [37]. Although more recent studies are available on the
relationship between calcium intake and osteoporotic frac-
ture, this study mentioned a dose–response relationship. In
another meta-analysis, it was found that a supplement of 500
to 1,200 mg calcium would reduce the risk of hip fracture
with 12 % (RR 0.88; 95 % CI 0.83–0.95) [50]. This study
only took into account randomized controlled trials, with
calcium supplementation as intervention. However, both
studies are concordant. Recently, a meta-analysis by
Bischoff-Ferrari et al. did not find a significant reduction
in hip fracture by drinking milk for men and women [51].
However, by deleting a Swedish study (considered to be an
outlier) from their analyses, the authors found a statistically
significant risk reduction of 5 %. Also in a meta-analysis by
Kanis et al. [44], it was found that a low intake of milk was
not associated with a marked increase in hip fracture risk.
However, low intake was defined as drinking less than one
glass of milk daily. Dairy products such as cheese and
yogurt were not taken into account. We defined low calcium
intake to be under 600 mg, we took a risk reduction of 8 %
based on the data of Cumming et al [37], thereby following
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a conservative approach. Finally, our approach was sup-
ported by the results of a recent population-based cohort
study by Warensjö et al. In this study, it was found that a
dietary calcium intake below approximately 700 mg per day
in women was associated with an increased risk of hip
fracture [52]. This risk estimate was somewhat higher than
in our study. However, this comprehensive study was not
specifically directed at dairy calcium intake.
We only used low calcium intake as risk factor for the
occurrence of hip fractures. However, there are other factors
that intervene with the effect of calcium on bone quality and
hip fractures, in particular vitamin D, which plays a crucial
role in calcium absorption [51]. It has been shown that there
was not much difference between calcium supplementation
alone (almost the DRI) or calcium combined with vitamin D
on reducing osteoporotic fractures [50, 53]. This is in line
with the conditions of use as determined by the European
Food Safety Authority that indicate 1,200 mg of calcium
per day, or 1,200 mg of calcium and 20 μg of vitamin D
per day for women aged 50 years and older (http://
www.efsa.europa.eu/). However, if dietary calcium is a
threshold nutrient, then that threshold for optimal calcium
absorption may be achieved at a lower calcium intake when
vitamin D levels are adequate [51]. In this respect, it should be
mentioned that the occurrence of dairy food fortification with
vitamin D might have been of some influence on the results of
our model. However, accurate information on the consump-
tion of such products was not readily available. Besides such a
fortification, dairy products themselves contain additional
nutrients that are beneficial to bone health, e.g. high protein
content [54]. Unfortunately, the literature does not provide
valid risk-estimates for osteoporotic fractures given the addi-
tional elements in dairy foods. In this regard, the results of this
study might give an underestimation about the effect size of
dairy calcium. Moreover, other factors mediate the effect of
calcium on bone health, and concomitantly on osteoporotic
fractures. These factors include exposure to sunlight, level of
exercise, and genetic predisposition [55]. Considering the
foregoing, it may be expected that there are differences in
the relative risk of hip fractures between the populations of
different countries.
Our analysis concentrated on the effects of dairy calcium
on hip fractures. Two observations need to be made about
this. First, we did not include osteoporotic fractures other
than hip fractures, due to the unavailability of sufficient
data. As a result, our model may have underestimated the
beneficial effects of dairy calcium. On the other hand, a side
effect of consuming more dairy products might be the intake
of more saturated fat, considered a risk factor for vascular
diseases. Although dairy products make a contribution to
total fat consumption, this contribution is likely to be rela-
tively small. Moreover, a review by Elwood et al. [5]
showed that there was no convincing evidence of any
increased risk of ischaemic heart disease or ischaemic stroke
in subjects who have the highest milk consumption.
For all countries in this study, the loss in quality of life
following a hip fracture was based on data from a Swedish
study [38] because country-specific data were not available.
This should not be considered too much of a limitation, as
the quality of life impact of hip fractures is not expected to
differ much between countries—not as much as costs might
do. Other ‘international’ health-economic studies in the field
of osteoporosis followed a similar approach: in these stud-
ies, the effect of fractures on quality of life was not based on
country-specific sources; whereas for the costs, country-
specific data were available [56–59].
Conclusions
Our study shows that, especially for France and Sweden, the
societal burden of hip fractures associated with low calcium
intake is quite substantial. Improving the dairy consumption
is likely to be effective in decreasing this public health
burden and the associated health care expenditures. Our
findings support the use of a food-based approach to help
maintain bone health or prevent age-related bone loss. This
is in line with the position of the French Agency for the
Safety of Health Products (AFSSAPS) which recommends
to correct calcium and/or vitamin D deficiencies before
prescribing anti-osteoporotic drugs [60]. It would be worth
performing a cost-effectiveness analysis of a community-
based educational health campaign. Behavioral changes,
especially related to diet and exercise, form the backbone
of public health recommendations for the prevention and
treatment of osteoporosis [61], are supported by several
RCTs [62, 63] and meta-analyses [50, 64, 65]. Yet, the
cost-effectiveness of such recommendations remains largely
unexplored.
Our model had to rely on the existing figures that do
not take into account the long-term advantages of pre-
vention, mainly focusing on the senior population where
bone density is already affected and where dietary inter-
ventions will complete the clinical management of diag-
nosed osteoporosis [66]. Yet, it is no less important to
focus on younger people as well, because eating practices
established in childhood are likely to be maintained
throughout life, and an adequate calcium intake during
childhood and adolescence, necessary for the develop-
ment of peak bone mass, may contribute to bone strength
and reduce the risk of osteoporosis and fractures later in
life [67, 68].
Although the methods may be further refined, this model
appears to be a solid and straightforward, easy-to-use meth-
od to assess the health, well-being and cost outcomes of
food products from a health economics perspective.
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